List of Trillium Therapeutics patents | 7 results

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 7351875 FcγRIIa transgenic animal model for autoimmune disease	Patent 7351875 was granted and assigned to Trillium Therapeutics on April, 2008 by the United States Patent and Trademark Office.		Trillium Therapeutics	United States Patent and Trademark Office	7351875	April 1, 2008
‌ US Patent 10906954 Treatment of CD47+ disease cells with SIRPα-Fc fusions	Patent 10906954 was granted and assigned to Trillium Therapeutics on February, 2021 by the United States Patent and Trademark Office.	Trillium Therapeutics	Trillium Therapeutics	United States Patent and Trademark Office	10906954	February 2, 2021
‌ US Patent 10696670 Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins	Patent 10696670 was granted and assigned to Trillium Therapeutics on June, 2020 by the United States Patent and Trademark Office.	Trillium Therapeutics	Trillium Therapeutics	United States Patent and Trademark Office	10696670	June 30, 2020
‌ US Patent 9441012 Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors	Patent 9441012 was granted and assigned to Trillium Therapeutics on September, 2016 by the United States Patent and Trademark Office.		Trillium Therapeutics	United States Patent and Trademark Office	9441012	September 13, 2016
‌ US Patent 7910770 Fc receptor modulating compounds and compositions	Patent 7910770 was granted and assigned to Trillium Therapeutics on March, 2011 by the United States Patent and Trademark Office.		Trillium Therapeutics	United States Patent and Trademark Office	7910770	March 22, 2011
‌ US Patent 10428030 Heterocycle derivatives and their use for the treatment of CNS disorders	Patent 10428030 was granted and assigned to Trillium Therapeutics on October, 2019 by the United States Patent and Trademark Office.	Trillium Therapeutics	Trillium Therapeutics	United States Patent and Trademark Office	10428030	October 1, 2019
‌ US Patent 10604476 Fluorinated amide derivatives and their uses as therapeutic agents	Patent 10604476 was granted and assigned to Trillium Therapeutics on March, 2020 by the United States Patent and Trademark Office.	Trillium Therapeutics	Trillium Therapeutics	United States Patent and Trademark Office	10604476	March 31, 2020